BRIEF—BioNTech announces $500 million shares buyback

The management board of BioNTech, with the approval of the supervisory board, resolved to carry out a share buyback program of American Depositary Shares (ADSs) of BioNTech (ISIN: US09075V1026) with a value of up to $5 million.

BioNTech, the German company that has developed Comirnaty, the world’s most successful COVID-19 vaccine in partnership with Pfizer, expects to use all or a portion of the repurchased ADSs to satisfy upcoming settlement obligations under BioNTech’s share-based payment arrangements.

The buyback will commence on June 2, 2023, on the US Nasdaq stock exchange and will be conducted within a six-month period up to November 2, 2023.